Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
CLEVELAND, May 9, 2011 /PRNewswire/ -- Mentor, Ohio-based Frantz Medical Group announced the immediate promotion of Stephanie A. S. Harrington, M.S. to Chief Operating Officer. Ms. Harrington joined Frantz Medical Group in 2005 as Vice President, Research & Business Development. Since that time, she has assumed increased responsibilities such as direct management of regulatory affairs and quality assurance, manufacturing and molding/tool room operations. Ms. Harrington has also served as the Chief Operating Officer for VasoStar (cardiovascular minimally invasive device to open arterial blockages), CardioStar (non-invasive blood pressure monitor) and NanoMed (cardiovascular stent surface technology), and the Vice President of Merlot Orthopedics (orthopedic fixation devices). Each of these companies is a Frantz Medical joint venture/equity company, and she will continue to directly manage these various operations.
Ms. Harrington is a Chemical Engineer with an undergraduate degree from the University of Maryland, and graduate degree from Stanford University. She has been focused in the medical device field for the past 16 years with extensive experience in new product development, regulatory affairs and quality assurance. She has previously held senior management positions at Imalux and STERIS.
Ms. Harrington has spearheaded the cardiovascular and orthopedic R&D initiatives at Frantz Medical Group, including industrial-sponsored and state and national funded research grants with leading institutional partners such as Cleveland Clinic, Global Cardiovascular Innovation Center, Stanford University, and University of Virginia. Ms. Harrington will be involved in all operational aspects for the Frantz Medical Group of companies, including Frantz Tool & Design, and will serve as an advisor for tactical and strategic input on Frantz Medical Group's bioscience seed initiatives.
"I highly value Stephanie's input and leadership in all aspects of our operations, and look forward to her even further expanded role as my colleague in Frantz Medical Group," said Mark G. Frantz, Chairman and CEO.
About Frantz Medical Group
Frantz Medical Group (FMG) has been transforming innovative concepts into commercially successful medical devices, both electromechanical and disposable products, since 1979. As an ISO 13485-certified, FDA-registered medical device company, FMG offers inventors and early-stage companies the infrastructure to design, verify, and transfer to production new medical devices efficiently and cost-effectively. FMG's manufacturing capabilities include high-volume injection molding, assembly, inspection, and packaging with both clean room and open manufacturing areas. For high volume products, FMG designs products for later-stage automation, and has implemented in-house automation, lowering labor requirements and per-piece costs.
For further information regarding Frantz Medical Group, please refer to the website: www.frantzgroup.com.
SOURCE Frantz Medical Group